{"entity":{"id":"tasca-therapeutics","kind":"company","name":"Tasca Therapeutics","aka":[],"tldr":"Tasca Therapeutics makes pills that block cancer-driving proteins by plugging a pocket where the protein normally holds a fatty molecule. Its first medicine, CP-383, began its first human trial in advanced solid tumours in September 2025.","summary":"Tasca Therapeutics is a clinical-stage company whose discovery platform identifies and maps lipid-binding pockets on proteins, including sites on auto-palmitoylated proteins, and designs small molecules against them. Its first-in-class lead, CP-383, is designed to modulate an oncogenic signalling pathway that the company has not named publicly; the launch release said it would first be evaluated in small cell lung, colorectal, head and neck and brain cancers. Tasca launched on 10 December 2024 with a USD 52 million Series A co-led by Regeneron Ventures and Cure Ventures with participation from the Invus Group, and on 16 September 2025 announced the first patient dosed in a phase 1/2 dose escalation and expansion trial of CP-383 in advanced solid tumours. Scientific founders are Xu Wu, David Fisher and Duojia Pan; co-founder Milenko Cicmil is chief executive.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.tascatx.com/"},{"label":"Series A launch release, December 2024","url":"https://www.tascatx.com/dec-10-press-release"},{"label":"First patient dosed release, September 2025","url":"https://www.tascatx.com/sept-18-press"}],"tags":[],"related":[],"cancers":["sclc","colorectal","head-and-neck","glioblastoma"],"sections":["targeted-therapy","drug-discovery"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated; the site footer carries a 2022 copyright notice, which is not treated as a founding date. The pathway and protein that CP-383 acts on are not named on the company pages read, so no target is linked; no technology is linked because no technology record matches small molecules that bind lipid pockets, and the company does not describe its platform as AI-driven. The ClinicalTrials.gov number of the CP-383 trial was not stated on the release."],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.tascatx.com/","stage":"startup","investors":[],"funding":[{"round":"Series A","year":2024,"amountUsd":52000000,"source":"https://www.tascatx.com/dec-10-press-release","note":"Co-led by Regeneron Ventures and Cure Ventures, with the Invus Group"}]},"route":"/companies/tasca-therapeutics/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"section":[{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}]}}